Screener / SEC EDGAR /CIK 0000939767 /10-K filed Feb 10, 2026, compared with Feb 11, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Exelixis, Inc. EXEL

Compare with peers Embed
FY2025 at a glance

Sales up 7.0%, free cash flow up to $875.8M

XBRL, from each 10-K
RevenueStatements
$2.3B from $2.2B in FY2024
FY2016FY2025
Net incomeStatements
$782.6M from $521.3M in FY2024
FY2016FY2025
Free cash flowStatements
$875.8M from $671.5M in FY2024
FY2016FY2025
EPS (diluted)Statements
$2.78 from $1.76 in FY2024
FY2016FY2025
Operating marginStatements
37.6% from 27.9% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
3.34
Sales (ttm)
2.5B
Net income (ttm)
885.1M
Sales growth
+7.0%
EPS growth
+58.0%
Sales Q/Q
+10.2%
Free cash flow
1.2B
Gross margin
96.3%
Oper. margin
40.2%
Net margin
35.5%
FCF margin
46.5%
R&D / sales
35.6%
Dividend
-
Debt/Eq
-
Curr. ratio
3.21
Cash
304.8M
Op. cash flow (ttm)
1.2B
EBITDA
901.2M
EBITDA margin
38.8%
Quick ratio
3.16
FCF after stock pay
762.9M
Goodwill / assets
2.2%
Oper. margin low 5y
9.3%
Stock pay / sales
4.9%
Shares out.
244.0M
Shares Y/Y
-4.8%
Book / share
7.52
Cash / share
1.25
Sales / share
10.23
Asset turnover
0.99
Inventory turns
3.86
Days sales out.
45
Sales 3Y CAGR
+12.9%
Sales 5Y CAGR
+18.6%
EPS 3Y CAGR
+70.3%
EPS 5Y CAGR
+51.3%
Employees
1,077
Sales / employee
2.3M

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 2.3B +31.9% a year Net income 782.6M
FY2016 revenue 191.5M · Revenues, 0000939767-17-000019 FY2016 net income -70.2M · NetIncomeLoss, 0000939767-17-000019 191.5M FY2016 FY2017 revenue 452.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000939767-20-000035 FY2017 net income 154.2M · NetIncomeLoss, 0000939767-20-000035 452.5M FY2017 FY2018 revenue 853.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000939767-20-000035 FY2018 net income 690.1M · NetIncomeLoss, 0001628280-21-001852 853.8M FY2018 FY2019 revenue 967.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000939767-22-000026 FY2019 net income 321.0M · NetIncomeLoss, 0000939767-22-000026 967.8M FY2019 FY2020 revenue 987.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0000939767-23-000019 FY2020 net income 111.8M · NetIncomeLoss, 0000939767-23-000019 987.5M FY2020 FY2021 revenue 1.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000939767-24-000028 FY2021 net income 231.1M · NetIncomeLoss, 0000939767-24-000028 1.4B FY2021 FY2022 revenue 1.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000939767-25-000019 FY2022 net income 182.3M · NetIncomeLoss, 0000939767-25-000019 1.6B FY2022 FY2023 revenue 1.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000939767-26-000021 FY2023 net income 207.8M · NetIncomeLoss, 0000939767-26-000021 1.8B FY2023 FY2024 revenue 2.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000939767-26-000021 FY2024 net income 521.3M · NetIncomeLoss, 0000939767-26-000021 2.2B FY2024 FY2025 revenue 2.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000939767-26-000021 FY2025 net income 782.6M · NetIncomeLoss, 0000939767-26-000021 2.3B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

From the same starting line, FY2016 to FY2025

Revenue, net income and free cash flow, each set to 100 in FY2016. What happened, from the 10-Ks. Not a forecast.

FY2016 = 100
500 1000 100 Revenue: $191.5M in FY2016, $2.3B in FY2025 REVENUE $2.3B · 12.1x Free cash flow: $204.6M in FY2016, $875.8M in FY2025 FREE CASH FLOW $875.8M · 4.3x FY2016 = 100FY2021FY2025
Revenue 12.1x $191.5M to $2.3B
Free cash flow 4.3x $204.6M to $875.8M

Growth per share, FY2016 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +24.2% a year FY2017 $0.49 to FY2025 $2.78, 8 years
Book value per share +30.4% a year FY2017 $0.91 to FY2025 $7.67, 8 years
Free cash flow per share +26.8% a year FY2017 $0.46 to FY2025 $3.11, 8 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Jan 2, 2026 $2.78$7.67$3.11
Jan 3, 2025 $1.76$7.58$2.27
Dec 29, 2023 $0.65$7.04$0.91
Dec 30, 2022 $0.56$7.67$1.03
Dec 31, 2021 $0.72$6.86$1.08
Jan 1, 2021 $0.35$5.91$0.56
Jan 3, 2020 $1.02$5.35$1.63
Dec 28, 2018 $2.21$4.12$1.22
Dec 29, 2017 $0.49$0.91$0.46
Dec 31, 2016 ---
Dec 30, 2016 -$0.28$0.36$0.83

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.4B
  • − All liabilities $683.1M
  • = Net current asset value $760.2M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $2.2B
  • − Goodwill $63.7M
  • = Tangible book value $2.1B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

EXEL against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+7.0%100th of 155 · median +10.5%
Net margin
-4.1%15.3%
35.5%5th of 154 · median 6.8%
Return on equity
-5.2%18.5%
48.3%9th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
46.5%3rd of 145 · median 10.0%
EXEL and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
EXEL Exelixis, Inc.$2.5B +7.0%96.3%35.5%48.3%46.5%-
RPRX Royalty Pharma plc$2.6B +5.1%-25.7%6.9%-0.88
QDEL QuidelOrtho Corp$2.6B -1.9%--14.2%-20.6%-4.5%1.64
MRNA Moderna$2.5B -39.9%--110.5%-40.8%-78.0%0.09
PRVA Privia Health Group, Inc.$2.4B +22.3%-1.4%4.3%--
RDNT RadNet, Inc.$2.4B +11.5%--0.9%-2.0%-1.18
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by region

From $1.4B of sales to $231.1M of profit FY2021

  • U.S. $1.1B
  • Europe $302.1M
  • Japan $43.5M
Revenue to Gross profit: $1.4BRevenue to Cost of revenue: $52.9MGross profit to Operating profit: $286.7MGross profit to Operating expenses: $1.1BOperating profit to Net profit: $231.1MOperating profit to Tax & other: $55.6MOperating expenses to R&D: $693.7MOperating expenses to SG&A: $401.7M Revenue: $1.4B REVENUE $1.4B +45% Y/Y Gross profit: $1.4B · 96% margin GROSS PROFIT $1.4B 96% margin Cost of revenue: $52.9M · 4% of revenue COST OF REVENUE $52.9M 4% of revenue Operating profit: $286.7M · 20% margin OPERATING PROFIT $286.7M 20% margin · +160% Y/Y Operating expenses: $1.1B · 76% of revenue OPERATING EXPENSES $1.1B 76% of revenue Net profit: $231.1M · 16% margin NET PROFIT $231.1M 16% margin · +107% Y/Y Tax & other: $55.6M · 4% of revenue TAX & OTHER $55.6M 4% of revenue R&D: $693.7M · 48% of revenue R&D $693.7M 48% of revenue SG&A: $401.7M · 28% of revenue SG&A $401.7M 28% of revenue

From $1.6B of sales to $182.3M of profit FY2022

  • U.S. $1.4B
  • Europe $168.6M
  • Japan $28.7M
Revenue to Gross profit: $1.6BRevenue to Cost of revenue: $57.9MGross profit to Operating profit: $201.5MGross profit to Operating expenses: $1.4BOperating profit to Net profit: $149.4MOperating profit to Tax: $52.1MOther income to Net profit: $32.9MOperating expenses to R&D: $891.8MOperating expenses to SG&A: $459.9M Revenue: $1.6B REVENUE $1.6B +12% Y/Y Gross profit: $1.6B · 96% margin GROSS PROFIT $1.6B 96% margin Cost of revenue: $57.9M · 4% of revenue COST OF REVENUE $57.9M 4% of revenue Operating profit: $201.5M · 13% margin OPERATING PROFIT $201.5M 13% margin · −30% Y/Y Other income: $32.9M · 2% of revenue OTHER INCOME $32.9M 2% of revenue Operating expenses: $1.4B · 84% of revenue OPERATING EXPENSES $1.4B 84% of revenue Net profit: $182.3M · 11% margin NET PROFIT $182.3M 11% margin · −21% Y/Y Tax: $52.1M · 3% of revenue TAX $52.1M 3% of revenue R&D: $891.8M · 55% of revenue R&D $891.8M 55% of revenue SG&A: $459.9M · 29% of revenue SG&A $459.9M 29% of revenue

From $1.8B of sales to $207.8M of profit FY2023

  • U.S. $1.6B
  • Europe $145.0M
  • Japan $39.5M
Revenue to Gross profit: $1.8BRevenue to Cost of revenue: $72.5MGross profit to Operating profit: $170.9MGross profit to Operating expenses: $1.6BOperating profit to Net profit: $121.1MOperating profit to Tax: $49.8MOther income to Net profit: $86.6MOperating expenses to R&D: $1.0BOperating expenses to SG&A: $542.7M Revenue: $1.8B REVENUE $1.8B +14% Y/Y Gross profit: $1.8B · 96% margin GROSS PROFIT $1.8B 96% margin Cost of revenue: $72.5M · 4% of revenue COST OF REVENUE $72.5M 4% of revenue Operating profit: $170.9M · 9% margin OPERATING PROFIT $170.9M 9% margin · −15% Y/Y Other income: $86.6M · 5% of revenue OTHER INCOME $86.6M 5% of revenue Operating expenses: $1.6B · 87% of revenue OPERATING EXPENSES $1.6B 87% of revenue Net profit: $207.8M · 11% margin NET PROFIT $207.8M 11% margin · +14% Y/Y Tax: $49.8M · 3% of revenue TAX $49.8M 3% of revenue R&D: $1.0B · 57% of revenue R&D $1.0B 57% of revenue SG&A: $542.7M · 30% of revenue SG&A $542.7M 30% of revenue

From $2.2B of sales to $521.3M of profit FY2024

  • U.S. $1.8B
  • Europe $318.6M
  • Japan $27.1M
Revenue to Gross profit: $2.1BRevenue to Cost of revenue: $76.2MGross profit to Operating profit: $604.6MGross profit to Operating expenses: $1.5BOperating profit to Net profit: $444.2MOperating profit to Tax: $160.4MOther income to Net profit: $77.0MOperating expenses to R&D: $910.4MOperating expenses to Sales, admin & other: $577.5M Revenue: $2.2B REVENUE $2.2B +18% Y/Y Gross profit: $2.1B · 96% margin GROSS PROFIT $2.1B 96% margin Cost of revenue: $76.2M · 4% of revenue COST OF REVENUE $76.2M 4% of revenue Operating profit: $604.6M · 28% margin OPERATING PROFIT $604.6M 28% margin · +254% Y/Y Other income: $77.0M · 4% of revenue OTHER INCOME $77.0M 4% of revenue Operating expenses: $1.5B · 69% of revenue OPERATING EXPENSES $1.5B 69% of revenue Net profit: $521.3M · 24% margin NET PROFIT $521.3M 24% margin · +151% Y/Y Tax: $160.4M · 7% of revenue TAX $160.4M 7% of revenue R&D: $910.4M · 42% of revenue R&D $910.4M 42% of revenue Sales, admin & other: $577.5M · 27% of revenue SALES, ADMIN & OTHER $577.5M 27% of revenue

From $2.3B of sales to $782.6M of profit FY2025

  • U.S. $2.1B
  • Europe $154.2M
  • Japan $25.6M
Revenue to Gross profit: $2.2BRevenue to Cost of revenue: $83.7MGross profit to Operating profit: $872.2MGross profit to Operating expenses: $1.4BOperating profit to Net profit: $713.6MOperating profit to Tax: $158.6MOther income to Net profit: $69.0MOperating expenses to R&D: $825.0MOperating expenses to Sales, admin & other: $539.2M Revenue: $2.3B REVENUE $2.3B +7% Y/Y Gross profit: $2.2B · 96% margin GROSS PROFIT $2.2B 96% margin Cost of revenue: $83.7M · 4% of revenue COST OF REVENUE $83.7M 4% of revenue Operating profit: $872.2M · 38% margin OPERATING PROFIT $872.2M 38% margin · +44% Y/Y Other income: $69.0M · 3% of revenue OTHER INCOME $69.0M 3% of revenue Operating expenses: $1.4B · 59% of revenue OPERATING EXPENSES $1.4B 59% of revenue Net profit: $782.6M · 34% margin NET PROFIT $782.6M 34% margin · +50% Y/Y Tax: $158.6M · 7% of revenue TAX $158.6M 7% of revenue R&D: $825.0M · 36% of revenue R&D $825.0M 36% of revenue Sales, admin & other: $539.2M · 23% of revenue SALES, ADMIN & OTHER $539.2M 23% of revenue

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax, less other income
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 36.2% FY2020: 5.9% net income ÷ equity
Net margin 33.7% FY2020: 11.3% profit per $ of sales: 782.6M ÷ 2.3B
Asset turnover 0.82× FY2020: 0.46× sales per $ of assets: 2.3B ÷ 2.8B
Leverage 1.32× FY2020: 1.14× assets per $ of equity: 2.8B ÷ 2.2B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    35.5% vs 6.8%
  • Return on equity above 15%
    48.3%
  • A profit in 9 of 10 years
Net margin, FY2016 to FY2025: -36.7% to 33.7%

Cash and shareholders

  • Free cash flow positive in every one of 10 years
    $875.8M last year
  • Share count down over 5 years
    −11.4%
  • Cash from operations above net income
    $884.3M vs $782.6M
Free cash flow, FY2016 to FY2025: 204.6M to 875.8M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $5.1M cash received before delivery, not yet recognized as revenue, Oct 2, 2026 · +33.7% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

EXEL's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue2.3B
FY2016: 191.5MFY2017: 452.5MFY2018: 853.8MFY2019: 967.8MFY2020: 987.5MFY2021: 1.4BFY2022: 1.6BFY2023: 1.8BFY2024: 2.2BFY2025: 2.3B FY2017FY2019FY2021FY2023FY2025
Net income782.6M
FY2016: -70.2MFY2017: 154.2MFY2018: 690.1MFY2019: 321.0MFY2020: 111.8MFY2021: 231.1MFY2022: 182.3MFY2023: 207.8MFY2024: 521.3MFY2025: 782.6M FY2017FY2019FY2021FY2023FY2025
Free cash flow875.8M
FY2016: 204.6MFY2017: 144.5MFY2018: 382.4MFY2019: 514.1MFY2020: 178.6MFY2021: 346.6MFY2022: 334.9MFY2023: 292.9MFY2024: 671.5MFY2025: 875.8M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay762.9M
FY2016: 181.7MFY2017: 120.5MFY2018: 341.8MFY2019: 457.5MFY2020: 73.6MFY2021: 226.8MFY2022: 227.3MFY2023: 186.5MFY2024: 577.7MFY2025: 762.9M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)2.78
FY2016: -0.28FY2017: 0.49FY2018: 2.21FY2019: 1.02FY2020: 0.35FY2021: 0.72FY2022: 0.56FY2023: 0.65FY2024: 1.76FY2025: 2.78 FY2017FY2019FY2021FY2023FY2025
Diluted shares281.9M
FY2016: -FY2017: 312.0MFY2018: 312.8MFY2019: 315.0MFY2020: 318.0MFY2021: 322.4MFY2022: 324.6MFY2023: 321.5MFY2024: 296.1MFY2025: 281.9M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Jan 2, 2026
RevenueSharevs year before
Gross product revenues 3.0B129.8% +19.6%
CABOMETYX 2.1B91.1% +17.5%
License revenues 214.4M9.2% -38.6%
Collaboration revenues 197.3M8.5% -45.1%
COMETRIQ 9.4M0.4% -15.4%
Discounts and allowances -889.0M-38.3% -

10-K 0000939767-26-000021, segment and revenue notes (XBRL).

Revenue by region

year to Jan 2, 2026
RevenueSharevs year before
U.S. 2.1B92.3% +17.4%
Europe 154.2M6.6% -51.6%
Japan 25.6M1.1% -5.5%

10-K 0000939767-26-000021, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue191.5M452.5M853.8M967.8M987.5M1.4B1.6B1.8B2.2B2.3B
Cost of revenue6.6M15.1M26.3M33.1M36.3M52.9M57.9M72.5M76.2M83.7M
R&D96.0M112.2M182.3M337.0M547.9M693.7M891.8M1.0B910.4M825.0M
SG&A116.1M159.3M206.4M228.2M293.4M401.7M459.9M542.7M492.1M518.7M
Operating income-28.1M165.9M438.9M369.5M110.1M286.7M201.5M170.9M604.6M872.2M
Interest expense33.1M8.7M00------
Pretax income-70.2M158.6M452.1M398.1M130.8M-----
Income tax04.3M-238.0M77.1M19.1M63.1M52.1M49.8M160.4M158.6M
Net income-70.2M154.2M690.1M321.0M111.8M231.1M182.3M207.8M521.3M782.6M
EPS (diluted)-0.280.492.211.020.350.720.560.651.762.78
Diluted shares-312.0M312.8M315.0M318.0M322.4M324.6M321.5M296.1M281.9M
Depreciation & amortization1.0M1.2M4.9M8.3M9.1M13.6M20.9M25.7M28.8M29.1M
EBITDA-27.1M167.1M443.8M377.8M119.2M300.3M222.4M196.6M633.4M901.2M
Operating margin-14.7%36.7%51.4%38.2%11.1%20.0%12.5%9.3%27.9%37.6%
Net margin-36.7%34.1%80.8%33.2%11.3%16.1%11.3%11.4%24.0%33.7%
Revenue growth+415%+136%+88.7%+13.3%+2.0%+45.3%+12.3%+13.6%+18.5%+7.0%
EPS growth--+351%-53.8%-65.7%+106%-22.2%+16.1%+171%+58.0%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow206.3M165.6M415.7M527.0M209.0M400.8M362.6M333.3M700.0M884.3M
Capital spending1.7M21.1M33.3M12.8M30.3M54.2M27.7M40.5M28.4M8.4M
Free cash flow204.6M144.5M382.4M514.1M178.6M346.6M334.9M292.9M671.5M875.8M
Stock-based pay (added back)22.9M23.9M40.6M56.6M105.1M119.8M107.6M106.3M93.8M113.0M
Free cash flow after stock pay181.7M120.5M341.8M457.5M73.6M226.8M227.3M186.5M577.7M762.9M
Buybacks-----00550.4M652.0M947.5M
Debt repaid-185.8M00------
Investing cash flow-216.0M36.8M-297.9M-587.2M-131.2M-42.9M-524.4M-27.0M-116.8M350.4M
Financing cash flow19.8M-169.9M9.7M12.6M-25.1M-14.8M586K-546.1M-628.8M-969.6M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)22.9M23.9M40.6M56.6M105.1M119.8M107.6M106.3M93.8M113.0M
Stock-based pay / revenue12.0%5.3%4.8%5.8%10.6%8.4%6.7%5.8%4.3%4.9%
Operating lease cost-3.9M4.2M2.8M4.8M5.3M18.3M29.0M27.5M23.9M
Operating lease cash paid--3.9M2.9M4.6M5.0M11.4M19.6M26.3M25.6M
Right-of-use assets-05.9M41.8M43.0M45.1M234.8M233.2M172.6M159.0M
Operating lease liabilities--14.8M50.7M52.1M56.4M207.8M215.7M215.8M200.9M
Finance lease liabilities--128K-------

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXEL/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.